Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ophtha.2008.10.020
Title: Atropine for the Treatment of Childhood Myopia: Effect on Myopia Progression after Cessation of Atropine
Authors: Tong, L.
Huang, X.L.
Koh, A.L.T.
Zhang, X.
Tan, D.T.H. 
Chua, W.-H.
Issue Date: Mar-2009
Citation: Tong, L., Huang, X.L., Koh, A.L.T., Zhang, X., Tan, D.T.H., Chua, W.-H. (2009-03). Atropine for the Treatment of Childhood Myopia: Effect on Myopia Progression after Cessation of Atropine. Ophthalmology 116 (3) : 572-579. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ophtha.2008.10.020
Abstract: Purpose: The aim of this study was to assess the effect on myopia progression after cessation of topical atropine treatment. Design: Parallel-group, placebo-controlled, randomized, double-masked study. Participants: Four hundred children aged 6 to 12 years with refractive error of spherical equivalent -1.00 to -6.00 diopters (D) and astigmatism of -1.50 D or less. Intervention: No intervention was administered. Subjects were followed up for 12 months after stopping treatment, which consisted of either 1% atropine or vehicle eyedrops once nightly for 2 years. Only 1 eye of each subject was chosen through randomization for treatment. Main Outcome Measures: The main efficacy outcome measures were change in spherical equivalent refraction as measured by cycloplegic autorefraction and change in ocular axial length as measured by ultrasonography. Results: After cessation of atropine drops, the mean progression in the atropine-treated group was -1.14±0.80 D over 1 year, whereas the progression in placebo-treated eyes was -0.38±0.39 D (P<0.0001). However, after 3 years of participation in the trial (with 2 years on atropine treatment), eyes randomized to atropine have less severe myopia than other eyes. Spherical equivalent was -4.29±1.67 D in the atropine-treated eyes compared with -5.22±1.38 D in the placebo-treated eyes (P<0.0001). Spherical equivalents in atropine-untreated and placebo-untreated eyes were -5.00±1.62 D and -5.28±1.43 D, respectively. Over the 3 years, the increase in axial length of the atropine-treated eyes was 0.29±0.37 mm compared with 0.52±0.45 mm in the placebo-treated eyes (P<0.0001). After cessation of atropine, the amplitude of accommodation and near visual acuity returned to pretreatment levels. Conclusions: After stopping treatment, eyes treated with atropine demonstrated higher rates of myopia progression compared with eyes treated with placebo. However, the absolute myopia progression after 3 years was significantly lower in the atropine group compared with placebo. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. © 2009 American Academy of Ophthalmology.
Source Title: Ophthalmology
URI: http://scholarbank.nus.edu.sg/handle/10635/92600
ISSN: 01616420
DOI: 10.1016/j.ophtha.2008.10.020
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

107
checked on Oct 15, 2018

WEB OF SCIENCETM
Citations

95
checked on Oct 15, 2018

Page view(s)

50
checked on Sep 21, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.